RESUMO
In the last decade, monitoring Marek's disease (MD) vaccination by real-time PCR has become a common practice. Evaluating in vivo replication of MD vaccines in the feather pulp (FP) at 7 days of age provides information on how well a flock has been vaccinated. Factors such as vaccine dose, combination with other vaccines, age and route of vaccination, and the origin of the vaccine can influence the results and need to be taken into consideration. Early infection with oncogenic MD virus (MDV) could also affect how vaccines replicate in the first week and therefore might influence the results. The objective of this study was to evaluate if coinfection with oncogenic MDV could affect MD vaccine DNA viral load in the FP at 7 days of age. A retrospective study was done using data from nine animal experiments (46 treatment groups) in which chickens were vaccinated against MD either in ovo or at 1 day of age and challenged with various oncogenic strains at 1 day of age by contact. In each experiment, vaccinated but not challenged groups were used as controls. Replication of MD vaccine was evaluated in samples of FP collected at 7 days of age by real-time PCR, and percentage of positives and vaccine load were analyzed. Our results show that CVI-988 (13 treatment groups), SB-1 (six treatment groups), and in most cases turkey herpesvirus (HVT; 24 out of 27 treatment groups) replication was not affected by early infection with oncogenic MDV. There were three treatment groups in which HVT replication differed between challenged and unchallenged chickens, however the effect was not clear; replication of HVT in nonchallenged chickens was higher (one treatment group) or lower (two treatment groups) than in challenged chickens and factors other than coinfection with MDV might have contributed to such differences.
Nota de investigaciónEl desafío temprano con un virus oncogénico de la enfermedad de Marek no interfiere con la carga de ADN de las vacunas contra la enfermedad de Marek en la pulpa de la pluma a los siete días de edad. En la última década, el seguimiento de la vacunación contra la enfermedad de Marek (EM) mediante PCR en tiempo real se ha convertido en una práctica común. La evaluación de la replicación in vivo de las vacunas de Marek en la pulpa de la pluma (FP) a los siete días de edad proporciona información sobre qué tan bien se ha vacunado una parvada. Factores como la dosis de la vacuna, la combinación con otras vacunas, la edad, la vía de vacunación y el origen de la vacuna pueden influir en los resultados y deben tenerse en cuenta. La infección temprana con un virus de Marek oncogénico (MDV) también podría afectar la forma en que las vacunas se replican en la primera semana y por lo tanto, podría influir en los resultados. El objetivo de este estudio fue evaluar si la coinfección con un virus de Marek oncogénico podría afectar la carga viral del ADN de la vacuna de Marek en la pulpa de la pluma a los siete días de edad. Se realizó un estudio retrospectivo utilizando datos de nueve experimentos con animales (46 grupos de tratamientos) en los que se vacunaron pollos contra la enfermedad de Marek ya sea in ovo o al día de edad y se desafiaron con varias cepas oncogénicas al día de edad por contacto. En cada experimento, se utilizaron como controles los grupos vacunados, pero no desafiados. Se evaluó la replicación de la vacuna de Marek en muestras de pulpa de la pluma recolectadas a los siete días de edad por PCR en tiempo real, y se analizó el porcentaje de positivos y la carga vacunal. Los resultados de este estudio muestran que la replicación de la cepa CVI-988 (13 grupos de tratamiento), la cepa SB-1 (seis grupos de tratamiento) y en la mayoría de los casos, del herpesvirus de pavo (HVT; 24 de 27 grupos de tratamiento) no se vio afectada por la infección temprana con un virus de Marek oncogénico. Hubo tres grupos de tratamiento en los que la replicación de la vacuna HVT difería entre pollos desafiados y no desafiados, sin embargo, el efecto no fue claro; la replicación de la vacuna HVT en pollos no desafiados fue mayor (un grupo de tratamiento) o menor (dos grupos de tratamiento) que en los pollos desafiados y otros factores distintos a la coinfección con el virus de la enfermedad de Marek podrían haber contribuido a tales diferencias.
Assuntos
Coinfecção , Herpesvirus Galináceo 2 , Vacinas contra Doença de Marek , Doença de Marek , Animais , Galinhas , Coinfecção/veterinária , DNA Viral , Plumas , Herpesvirus Galináceo 2/genética , Estudos RetrospectivosRESUMO
Md5-BAC-REV-LTR is a recombinant Marek's disease virus (MDV), with an insertion of the long terminal repeat (LTR) of reticuloendotheliosis virus (REV) into the genome of the highly virulent MDV strain rMd5. It has been shown that Md5-BAC-REV-LTR does not induce tumours and confers high protection against challenge with MDV in 15 × 7 chickens. The objective of the present study was to evaluate the protection and safety (in terms of oncogenicity and immunosuppression) of Md5-BAC-REV-LTR in commercial meat-type chickens bearing maternal antibodies against MDV. Our results show that sub-cutaneous administration of Md5-BAC-REV-LTR at 1 day of age conferred high protection (protection index PI = 84.2) against an early challenge (1 day) by contact exposure to shedder birds infected with the vv+ MDV 648A strain. In such stringent challenge conditions, Md5-BAC-REV-LTR was more protective than a commercial CVI988 (PI = 12.4) and similar to the experimental vaccine Md5-BACΔmeq (PI = 92.4). Furthermore, Md5-BAC-REV-LTR did not induce either tumours or immunosuppression in this study. Immunosuppression was evaluated by the relative lymphoid organ weights and also by the ability of the vaccine to induce late-MDV-induced immunosuppression associated with reactivation of the virus. This study shows that Md5-BAC-REV-LTR has the potential to be used as a MD vaccine and is highly protective against early challenge with vv+ MDV.RESEARCH HIGHLIGHTSMd5-BAC-REV-LTR is highly protective against early challenge with vv+ MDV in commercial meat-type chickens.Md5-BAC-REV-LTR does not cause early immunosuppression.Md5-BAC-REV-LTR does not cause late immunosuppression.Unlike other serotype 1 vaccines, Md5-BAC-REV-LTR is not detected in feather pulp at 7 days post vaccination.
Assuntos
Herpesvirus Galináceo 2 , Vacinas contra Doença de Marek , Vírus da Reticuloendoteliose , Animais , Galinhas , Terapia de Imunossupressão/veterinária , Vacinas contra Doença de Marek/genética , Carne , Sequências Repetidas Terminais/genéticaRESUMO
Understanding the pathogenesis of herpesvirus of turkeys (HVT) in its natural host is necessary before recombinant HVT (rHVT) can be used efficiently in turkey flocks. The objectives of this study were to evaluate when commercial turkey flocks get infected with wild type HVT, to study replication of HVT (conventional and recombinant rHVT-Newcastle disease, rHVT-ND) and other Marek's disease (MD) vaccines (SB-1 and CVI988) in turkey embryonic tissues, and to evaluate the expression of TLR-3 and IFN-γ in the lung and spleen of one-day-old turkeys after in ovo vaccination with MD vaccines. Our results demonstrated that commercial turkeys got exposed to wild type HVT within the first days of life; therefore, there is a potential of interaction between wild type HVT and rHVT when administered at day of age. On the other hand, all evaluated vaccines (especially HVT and rHVT-ND) replicated very well in turkey embryonic tissues. In ovo vaccination with HVT and CVI988 increased transcription of TLR-3 in the spleen of one-day-old turkeys. However, no effect on the transcription of TLR-3 or IFN-γ in the lungs and IFN-γ in the spleen in newly hatched turkeys was detected in the present study. Because of the limitations of evaluated genes, timepoints, and studied tissues, future studies are warranted to better understand the effect of MD vaccines on the turkey embryo immune responses.RESEARCH HIGHLIGHTS Commercial turkey flocks get infected with wild type HVT within the first days of life.HVT and rHVT replicates readily in turkey embryonic tissues.SB-1 and CVI988 also replicate in turkey embryonic tissues, but at lower rates than HVT and rHVT.HVT and CVI988 increase transcription of TLR-3 in the spleen.
RESUMO
Marek's disease (MD) vaccines are cell-associated and require special handling and care during administration. Vaccine dose is evaluated by plaque assay and is indicated as the number of plaque-forming units (PFUs) per dose. The objectives of this study were to evaluate the dose variability within each vial of MD vaccines and to assess those factors (from both manufacturing and handling and administration of the vaccine) that could affect vaccine dose variability. Three experiments were conducted. Experiment 1 was to evaluate dose variability in 36 MD vaccine vials and the effect of manufacturing factors on dose variability. Vaccines were titrated 10 times. Dose variability was measured as the coefficient of variability (CV) calculated as standard deviation divided by average PFU and multiplied by 100. Our results showed that all evaluated vaccines had levels of CV ranging from 10% to 34%. Variability existed regardless of manufacturer, vaccine serotype, and batch. Experiment 2 was conducted to evaluate the effect of infectivity rate (IR) on CV. IR was artificially reduced by adding noninfected chicken embryo fibroblast to the reconstituted vaccine before titration. Our results showed that decreased IR results in higher CV. Experiment 3 was to evaluate the handling and administration factors (time and mixing during administration) on CV. Our results showed that CV tends to increase with time and that this effect is more remarkable if vaccines were not mixed. Our study emphasizes the relevance of proper handling of MD vaccines and shows that dose variability can jeopardize the uniformity of vaccination in a flock and therefore the success of vaccination.
Evaluación de factores que influyen en la variabilidad de las dosis de las vacunas contra la enfermedad de Marek. Las vacunas contra la enfermedad de Marek (MD) están asociadas a células y requieren un manejo y cuidado especiales durante la administración. La dosis de la vacuna se evalúa mediante un ensayo de placa y se indica como el número de unidades formadoras de placa (UFP) por dosis. Los objetivos de este estudio fueron evaluar la variabilidad de la dosis dentro de cada vial de vacunas contra la enfermedad de Marek y evaluar los factores (tanto de fabricación como de manipulación/administración de la vacuna) que podrían afectar la variabilidad de la dosis de la vacuna. Se realizaron tres experimentos. El experimento número 1 consistió en evaluar la variabilidad de la dosis en 36 viales de vacuna de Marek y el efecto de los factores de fabricación en la variabilidad de la dosis. Las vacunas fueron tituladas 10 veces. La variabilidad de la dosis se midió como el coeficiente de variación (CV) calculado como desviación estándar dividido por las UFP promedio y multiplicado por 100. Nuestros resultados mostraron que todas las vacunas evaluadas tenían coeficientes de variación que variaban del 10% al 34%. La variabilidad existía independientemente del fabricante, el serotipo de la vacuna y el lote. El experimento número 2 se realizó para evaluar el efecto de la tasa de infectividad (IR) en el coeficiente de variación. La tasa de infectividad se redujo artificialmente mediante la adición de fibroblastos de embrión de pollo no infectados a la vacuna reconstituida antes de la valoración. Los resultados mostraron que la disminución en la tasa de infectividad resulta en mayores coeficientes de variación. El experimento número 3 consistió en evaluar los factores de manipulación y administración (tiempo y mezclado durante la administración) sobre los coeficientes de variación. Nuestros resultados mostraron que el coeficiente de variación tiende a aumentar con el tiempo y que este efecto es más notable si las vacunas no se mezclan. Este estudio enfatiza la relevancia del manejo adecuado de las vacunas contra la enfermedad de Marek y muestra que la variabilidad de la dosis puede poner en peligro la uniformidad de la vacunación en una parvada y por lo tanto el éxito de la vacunación.
Assuntos
Galinhas , Mardivirus/imunologia , Vacinas contra Doença de Marek/imunologia , Doença de Marek/prevenção & controle , Doenças das Aves Domésticas/prevenção & controle , Vacinação/veterinária , Animais , Embrião de Galinha , Relação Dose-Resposta ImunológicaRESUMO
In previous studies, we have demonstrated that very virulent plus Marek's disease viruses (vv+MDV) are highly immunosuppressive in commercial meat-type chickens. The specific objectives of this work were to evaluate if vv+MDV immunosuppression (MDV-IS) is induced by reduction of lymphocyte responsiveness and/or viability. Three experiments were conducted to (i) compare vv+MDV 686 with a partially attenuated 686-BAC; (ii) compare vv+MDV strains (648A and 686) with vMDV (GA) and vvMDV (Md5); and (iii) compare chickens vaccinated with Md5-BACΔMEQ and with CVI988 + HVT. In each experiment, spleens were collected at 28-30 days post infection and lymphocytes were isolated and investigated in three ways: their proliferative response to Concanavalin A (ConA) was analysed by MTT proliferation assay; cell death, and expression of CD45 and MHC-I was studied by flow cytometry; and MHC-IA and ß-2 microglobulin (B2M) expression was evaluated by real time RT-PCR. Splenocytes of chickens inoculated with vv+MDV were severely impaired to proliferate when exposed to ConA. Furthermore, vv+MDV induced severe splenocyte death that did not occur after infection with v or vvMDV strains. Vaccination with CVI988 + HVT, and at less level with Md5-BACΔMEQ reduced these negative effects. This is in contrast to our previous results in which Md5-BACΔMEQ but not CVI988 + HVT protected against MDV-IS suggesting that although cell death and decrease lymphocyte function seem to be related to MDV virulence and certainly will be associated with immunosuppression, they might not fully explain the previously reported MDV-IS. RESEARCH HIGHLIGHTS vv+MDV induces extensive death in splenocytes in meat-type chickens 28-30â dpi. vv+MDV impairs lymphocyte function in meat-type chickens 28-30â dpi. Vaccination protects against splenocyte death and reduced lymphocyte function. Cell lysis and reduced lymphocyte function do not fully explain MDV-IS.
Assuntos
Galinhas/virologia , Herpesvirus Galináceo 2/patogenicidade , Doença de Marek/virologia , Doenças das Aves Domésticas/virologia , Animais , Proliferação de Células , Galinhas/imunologia , Feminino , Terapia de Imunossupressão/veterinária , Baço/virologia , Linfócitos T/virologia , VirulênciaRESUMO
Several recombinant turkey herpesviruses (rHVTs) have been developed within the past decades, and they are now used commercially worldwide. In broiler chickens, rHVTs are usually administered alone, but in long-living birds they are used in combination with Marek's disease (MD) vaccines of other serotypes (i.e., CVI988). The objectives of this work were to 1) evaluate protection against MD conferred by HVT and two rHVTs when combined with CVI988 and 2) optimize the use of rHVT in combination with CVI988 to maximize replication of rHVT without compromising MD protection. Various vaccine protocols, all using rHVT or HVT at the recommended dose (RD), were evaluated. Protocols evaluated included in ovo vaccination with HVT+CVI988 or rHVT+CVI988 (using either the double dose [DD] or the RD of CVI988), day of age vaccination of rHVT+CVI988 at DD, and revaccination protocols using rHVT in ovo followed by CVI988 at DD at day of age. Our results show that, when combined with CVI988, HVT and rHVTs confer a similar level of protection against MD (>90%) regardless of whether CVI988 was used at RD or at DD. However, the combination of rHVT with CVI988 at DD resulted in reduced replication rates of rHVT (60%-76% vs. 95%-100%). Our results show that such a negative effect could be avoided without jeopardizing MD protection by administering CVI988 at RD (if combined in ovo with rHVT) or administered rHVT first in ovo followed by CVI988 at DD at day of age.
Estudio de la eficacia y replicación de vacunas con vectores recombinantes mediante el uso del virus del herpes del pavo combinado con otras vacunas contra la enfermedad de Marek. Varios herpesvirus de pavo recombinantes (rHVT) se han desarrollado en las últimas décadas y ahora se utilizan comercialmente en todo el mundo. En pollos de engorde, los rHVT generalmente se administran solos, pero en aves de vida larga se usan en combinación con vacunas contra la enfermedad de Marek (MD) de otros serotipos (especialmente, CVI988). Los objetivos de este trabajo fueron 1) evaluar la protección contra la enfermedad de Marek conferida por herpesvirus de pavo (HVT9 y por dos rHVT cuando se combinan con la cepa CVI988 y 2) optimizar el uso de rHVT en combinación con la cepa CVI988 para maximizar la replicación de rHVT sin comprometer la protección contra la enfermedad de Marek. Se evaluaron varios protocolos de vacunas, todos con rHVT o con HVT a la dosis recomendada (RD). Los protocolos evaluados incluyeron la vacunación in ovo con HVT + CVI988 o rHVT + CVI988 (usando la dosis doble o la dosis recomendada de la cepa CVI988), la vacunación al día de la edad con rHVT + CVI988 con dosis doble, y los protocolos de revacunación usando rHVT seguido por la cepa CVI988 con dosis doble al día de edad. Los resultados muestran que cuando se combinan con CVI988, HVT y rHVT confieren un nivel de protección similar contra la enfermedad de Marek (> 90%) independientemente de que la cepa CVI988 se haya usado a la dosis recomendada o con dosis doble. Sin embargo, la combinación de rHVT con la cepa CVI988 con doble dosis produjo una reducción en las tasas de replicación de rHVT (60% 76% vs. 95% 100%). Estos resultados muestran que dicho efecto negativo podría evitarse sin poner en peligro la protección contra la enfermedad de Marek administrando la cepa CVI988 a la dosis recomendada (si se combina in ovo con rHVT) o administrando rHVT primero in ovo, seguido de CVI988 con dosis doble al día de la edad.
Assuntos
Galinhas , Herpesvirus Meleagrídeo 1/imunologia , Herpesvirus Galináceo 2/imunologia , Vacinas contra Doença de Marek/farmacologia , Doença de Marek/prevenção & controle , Doenças das Aves Domésticas/prevenção & controle , Animais , Feminino , Doença de Marek/virologia , Doenças das Aves Domésticas/virologia , Vacinação/veterináriaRESUMO
Herpesvirus of turkeys (HVT) has been successfully used as a Marek's disease (MD) vaccine for more than 40 yr. Either alone (broiler chickens) or in combination with vaccines of other serotypes (broilers, broiler breeders, and layers), HVT is used worldwide. In recent years, several vector vaccines based on HVT (rHVT) have been developed. At present, there are both conventional HVT and rHVTs in the market, and it is unknown if all of them confer the same level of protection against MD. The objective of this study was to further characterize the protection conferred by two conventional HVTs (HVT-A and HVT-B) and three recombinant HVTs (rHVT-B, rHVT-C, and rHVT-D) against MD in broiler chickens. In a first study we evaluated the efficacy of two conventional HVTs (HVT-A and HVT-B) administered at different doses (475, 1500, and 4000 PFU) at day of age on the ability to protect against an early challenge with very virulent plus strain 645. In a second experiment we evaluated the protection ability of several HVTs (both conventional and recombinant) when administered in ovo at a dose of 1500 PFU using the same challenge model. Our results show that each HVT product is unique, regardless of being conventional or recombinant, in their ability to protect against MD and might require different PFUs to achieve its maximum efficacy. In Experiment 1, HVT-A at 4000 PFU conferred higher protection (protection index [PI] = 63) than any of the other vaccine protocols (PI ranging from 36 to 47). In Experiment 2, significant differences were found among vaccine protocols with PI varying from 66 (HVT-A) to 15 (rHVT-D). Our results show that each HVT is unique and age at vaccination and vaccine dose greatly affected vaccine efficacy. Furthermore, they highlight the need of following manufacturer's recommendations.
Assuntos
Galinhas , Herpesvirus Meleagrídeo 1/imunologia , Vacinas contra Doença de Marek/farmacologia , Doença de Marek/prevenção & controle , Doenças das Aves Domésticas/prevenção & controle , Vacinação/veterinária , Fatores Etários , Animais , Relação Dose-Resposta Imunológica , Feminino , Doença de Marek/virologia , Vacinas contra Doença de Marek/administração & dosagem , Doenças das Aves Domésticas/virologia , Vacinas Sintéticas/administração & dosagem , Vacinas Sintéticas/farmacologiaRESUMO
Somatic chromosome numbers were determined for 20 new germplasm accessions of Paspalum, belonging to 17 species collected in Brazil. Chromosome number is reported for the first time for P. reduncum (2n = 18), P. cinerascens (2n = 20), P. cordatum (2n = 20), P. filgueirasii (2n = 24), P. ammodes (2n = 36), P. bicilium (2n = 40), P. heterotrichon (2n = 40), and P. burmanii (2n = 48). New cytotypes were confirmed for two germplasm accessions of P. carinatum (2n = 30) and P. trachycoleon (2n = 36), one of P. clavuliferum (2n = 40) and one of P. lanciflorum (2n = 40), indicating variability in these species. The remaining chromosome numbers reported here confirm previous counts. The unexpected chromosome numbers 2n = 18, 24, 36, and 48 in Paspalum species, which are usually shown to be multiples of 10, suggest that much more collection and cytogenetic characterization are necessary to assess the whole chromosomal and genomic multiplicity present in the genus, which seems to be much more diverse than currently thought to be.
Assuntos
Cromossomos de Plantas/genética , Paspalum/genética , Brasil , Análise Citogenética , Mitose/genética , Paspalum/classificação , Filogenia , PoliploidiaRESUMO
Somatic chromosome numbers were determined for 20 new germplasm accessions of Paspalum, belonging to 17 species collected in Brazil. Chromosome number is reported for the first time for P. reduncum (2n = 18), P. cinerascens (2n = 20), P. cordatum (2n = 20), P. filgueirasii (2n = 24), P. ammodes (2n = 36), P. bicilium (2n = 40), P. heterotrichon (2n = 40), and P. burmanii (2n = 48). New cytotypes were confirmed for two germplasm accessions of P. carinatum (2n = 30) and P. trachycoleon (2n = 36), one of P. clavuliferum (2n = 40) and one of P. lanciflorum (2n = 40), indicating variability in these species. The remaining chromosome numbers reported here confirm previous counts. The unexpected chromosome numbers 2n = 18, 24, 36, and 48 in Paspalum species, which are usually shown to be multiples of 10, suggest that much more collection and cytogenetic characterization are necessary to assess the whole chromosomal and genomic multiplicity present in the genus, which seems to be much more diverse than currently thought to be.
Assuntos
Cromossomos de Plantas/genética , Paspalum/genética , Brasil , Análise Citogenética , Filogenia , Poliploidia , Paspalum/classificaçãoRESUMO
Reconstructing a cancer patient's head and neck region can be challenging for the restorative team because of the size of the defect and the tumorous condition of the remaining anatomical structures. This article presents a case that uses remaining healthy tissue, along with intraoral and extraoral devices, to deliver a sophisticated prosthetic device designed to restore physical function.
Assuntos
Neoplasias de Cabeça e Pescoço/reabilitação , Prótese Maxilofacial , Olho Artificial , Humanos , Magnetismo/uso terapêutico , Masculino , Implante de Prótese Maxilofacial/métodos , Modelos Anatômicos , Desenho de Prótese/métodosRESUMO
The use of a visible light-cure dental synthetic resin offers some advantages in the clinical delivery of an ocular prosthesis and a statistically significant reduction in the processing time.
Assuntos
Olho Artificial , Metacrilatos , Poliuretanos , HumanosRESUMO
Timely rehabilitation of facial defects necessitates provisional prostheses during the period following surgery. The possibilities of using microwave radiation in the drying of gypsum casts, the preparation of stone molds, the curing of silicone elastomers, and the extrinsic coloring of silicone prostheses are presented. Microwave radiation has the potential for saving time, energy, and resources during the fabrication of provisional facial prostheses.
Assuntos
Dimetilpolisiloxanos , Prótese Maxilofacial , Micro-Ondas , Desenho de Prótese , Materiais Biocompatíveis/efeitos da radiação , Sulfato de Cálcio/efeitos da radiação , Fenômenos Químicos , Físico-Química , Dessecação , Humanos , Elastômeros de Silicone/efeitos da radiação , Fatores de TempoRESUMO
Initial clinical studies applying the osseointegration concept for retention of facial prostheses have been encouraging. The results of these preliminary investigations indicate new treatment possibilities with facial prostheses anchored to the cranial skeleton by osseointegrated implants. Osseointegrated rehabilitation of the maxillofacial prosthetic patient presents the potential for overcoming many of the disadvantages associated with conventional retentive methods. Fabrication and support for facial prostheses by using osseointegrated implants for retention are described.
Assuntos
Ossos Faciais/cirurgia , Prótese Maxilofacial/métodos , Próteses e Implantes , Desenho de Prótese , Humanos , Magnetismo , NarizRESUMO
Topical drug therapy for ulcerative and vesiculobullous diseases of the oral mucosa has generally proved unsatisfactory because of the turbulent and changing nature of the oral cavity. The construction and use of an intraoral drug delivery system using custom carriers to deliver topical medication is described. The delivery system presented overcomes many of the obstacles associated with topical drug administration for oral lesions and provides a therapeutic alternative to systemic agents.